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ABSTRACT
Background
Thyroid nodules diseases are common, and fine-needle aspiration biopsy (FNAB)
is the first choice in distinguishing benign disease from malignant one. A part of
patients whose results of FNAB are indeterminate (Thy3, Thy4) underwent surgery
while postoperative pathology reported benign lesions. Serum thyrotropin (TSH) is a
known thyroid growth factor, and suppression of TSH concentrations by
administering exogenous thyroxine may influence the growth of established nodules
as well as the formation of new thyroid nodules, however the pathogenic role of TSH
in thyroid oncogenesis is unclear. The aim of this study is to examine the relationship
between preoperative TSH and differentiated thyroid cancer (DTC) and investigate
whether TSH at presentation can serve as a predictor of thyroid malignancy in
patients with thyroid nodules.
4Methods
Between 2011 and 2014, a total of 9774 patients underwent thyroid surgery in
our department. Data from 1287 patients without overt thyroid dysfunction with
preoperative serum TSH concentration were recorded. Age, gender, nodule number,
nodule size, preoperative fine-needle aspiration biopsy (FNAB), and serum TSH level
were assessed in relationship to the postoperative pathological outcomes. Patients
were divided into subgroups according to results of pathology, TSH level, DTC stage,
and patient’s age, then the relationship between TSH and thyroid cancer was
analyzed.
Results
The overall sensitivity and specificity of FNAB in predicting malignancy were
82.9% and 91.9%, respectively. 223 patients (17.3%) had DTC on final pathology.
Serum TSH levels in DTC patients (mean 1.20 ±0.1 uU/ml) were significantly higher
than in benign thyroid nodule disease (BTND) (mean 0.80 ±0.3uU/ml). The risk of
diagnosis of malignancy correlated with higher TSH level at presentation, with
significant higher rates of malignancy observed in patients with serum TSH greater
than 0.9 uU/ml, compared with those with lower TSH. The mean TSH was 2.80 ±1.6
uU/ml in patients with stage III/IV vs. 0.74±0.3 uU/ml in patients with stage I/II
(P=0.003). In thyroid auto-antibody (TAb) positive subjects, mean TSH level
(0.80±0.3 uU/ml) was significantly higher (P=0.002) than in TAb negative patients
(0.60±0.5 mU/m). Both in TAb positive and negative patients, serum TSH levels were
significantly higher in DTC than in BTND group. Mean TSH level was significantly
5higher in cancer patients regardless of age < 45 years or ≥ 45 years (P =0.045 and
0.028, respectively). When age groups < 30, 30–44, 45–59 and ≥60 years were
examined, it was found that there was a trend of rising mean TSH with age. Despite
the similar rise in the benign subgroups, mean TSH level was consistently higher in
those with cancer vs. those without. On multivariate analysis, higher TSH was
independently associated with cancer (P=0.039) but not with age (P=0.458). Binary
logistic regression analysis revealed significantly increased adjusted odds ratios (AOR)
for the diagnosis of malignancy in patients with serum TSH 0.60-0.89 uU/ml when
compared with those with TSH <0.60 uU/ml, with further increase evident in those
with TSH 0.9-1.59 uU/ml, 1.60-3.4 uU/ml, and greater than 3.4 uU/ml compared with
TSH<0.60 uU/ml. Males (AOR 2.42, 95% CI 1.53-3.57, P <0.0001), younger patients
(AOR 0.92, 95% CI 0.88-0.97, P=0.026), and those with solitary nodules (AOR 2.34,
95% CI 1.49-4.16, P=0.001) and smaller nodules (AOR 0.72, 95% CI 0.68-0.89,
P<0.0001) were also at an increased risk.
Conclusion
TSH is a known thyroid growth factor and the risk of malignancy in thyroid
nodules increased with higher serum TSH concentration. Even within normal TSH
ranges, an increased risk of DTC was found in a TSH level above the population
mean relative to a TSH level below the mean. In addition, higher serum TSH
concentration is related to advanced stage DTC. Despite unclear pathogenesis, the
association between thyroid cancer and higher TSH is independent of age. Serum
6TSH level may be able to serve as an adjunct to other well defined clinical parameters
and results of FNAB, especially for the indeterminate cytologic outcome.
Keywords: Thyrotropin (TSH), Differentiated thyroid cancer (DTC), Fine-needle
aspiration biopsy (FNAB), Thyroid nodule, Thyroid cytology, Thyroid histology,
7ABBREVIATIONS
FNAB = fine-needle aspiration biopsy;
TSH = thyrotropin (thyroid-stimulating hormone);
DTC=differentiated thyroid cancer;
BTND=benign thyroid nodule disease;
FT3=free triiodothyronine;
FT4=free thyroxine;
TAb=thyroid auto-antibody;
AOR=adjusted odds ratios;
CI=Confidence internal;
CT = computed tomography;
MTC=medullary thyroid carcinoma;
MEN 2 = multiple endocrine neoplasia type 2;
MNG = multinodular goiter;
MRI = magnetic resonance imaging;
PTC = papillary thyroid carcinoma;
rhTSH = recombinant human TSH;
TgAb=anti-thyroglobulin antibody;
TPOAb = anti–thyroid peroxidase antibody;
TRAb = anti–TSH receptor antibody;
UGFNAB = USguided FNAB
US = ultrasonography, ultrasonographic
8INTRODUCTION
Thyroid nodule is a very common clinical disease, with an approximate
prevalence of 4–7% by palpation (Vander et al. 1968; Tunbridge et al. 1977; Hegedus
2004). The Framingham study in the United States demonstrated a 5–10% lifetime
risk of developing a thyroid nodule (Vander et al. 1968), and the Whickham survey in
the northeast of England reported a 15% frequency of goiters or thyroid nodules
(Tunbridge et al. 1977). According to Framingham study, clinically discovered thyroid
nodules were present in 6.4% of females and 1.6% of males with an estimated annual
incidence, by palpation, of 1:1,000 (Vander et al. 1968). Additionally, by using
high-resolution ultrasound, thyroid nodules can be detected in 19–67% of individuals,
with higher frequencies in women and the elderly, even when the gland is normal to
palpation (Marqusee et al. 2000). There are ethnic, regional, gender and age
differences found by large epidemiological studies. There are also differences within
districts of the same country, mainly reflecting differences in iodine status and
goitrogens in water and food (Hegedus 2001; Knudsen et al. 2002; Marqusee et al.
2000; Reiners et al.2004).
However, only 5–15% of the clinically apparent thyroid nodules are malignant
(Belfiore et al. 1989; Frates et al. 2006; Werk et al. 1984). This fluctuation in the
proportions is due to different selection methods and different populations. Surgical
series have shown even higher rates, in a study of patients who underwent surgery
without previous fine-needle aspiration biopsy (FNAB), with the rate of malignant
9being 6.5% (Werk et al. 1984). The following series were exposure to radioactive
iodine in childhood, especially in iodine deficiency states (Cardis et al. 2006). African
Americans have the lower rate, whereas Caucasian and Asian have the highest (Hayat
et al. 2007). The annual incidence of thyroid carcinoma is 1–2 per 100,000
populations, which accounts for 90% of all endocrine malignancies, 1% of all human
malignancies and 0.5% of all deaths from malignancies. Although thyroid carcinoma
is usually not aggressive, they are responsible for more deaths than all other endocrine
malignancies (Landis et al. 1998). In most cases, thyroid carcinoma presents clinically
as a solitary nodule or as a dominant nodule within a multinodular thyroid gland
(Polyzos et al. 2007), meanwhile it is clinically difficult to distinguish thyroid glands
harboring malignancy from those who do not, and physical examination is therefore
regarded as largely unhelpful in identifying those patients with thyroid malignancy
(Hegedus et al. 2003). Minimizing the risk of overlooking thyroid cancer is the major
aim of clinical evaluation of patients presenting with thyroid nodules. Therefore,
about thyroid nodules doctor confront a diagnostic challenge, mainly because of the
need to preclude the little part of patients with thyroid cancer requiring surgical
intervention, avoiding unnecessary thyroid surgery in patients with benign nodules.
There are a number of well-established predictors of malignancy in thyroid
nodules, containing the finding of hard and fixed nodules on clinical examination,
rapid growth of nodules, associated hoarseness, dysphagia or lymphadenopathy,
although all of these symptoms and signs are relatively uncommon at diagnosis
process (Hegedus et al. 2003, Hegedus 2004). Further risk factors of thyroid
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malignancy are patient’s age under 30 or over 60 years, male sex (8 vs. 4% in female),
nodule size >4 cm, rapidly growing nodules (especially during suppressive thyroxine
therapy), history of head and neck irradiation and family history of medullary thyroid
carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) (Belfiore et al.
1992; Hegedus et al. 2003; Morganti et al. 2005; Polyzos et al. 2007; Tuttle et al.
1998).
Since simplicity, safety and cost-effectiveness of FNAB, it justifies it’s use for
selection of patients for surgery and is considered to be the “gold standard” in the
management of thyroid nodules, although several imaging methods are available
(Cooper et al. 2006; Garcia-Mayor et al. 1997; Pacini et al. 2006). FNAB has a
reported diagnostic sensitivity and specificity ranging between 65 and 98% and 72
and 100%, respectively (Sherman 2003; Mazzaferri 1993; Gharib et al. 1993). In
approximate 80% of cases, diagnostic FNAB results can be obtained, and repeat
aspiration can improve the accuracy of the procedure (Gharib et al. 1993; Castro et al.
2005). Several studies have indicated that US guided FNAB (UGFNAB), compared
with palpation-guided, reduces the number of nondiagnostic aspirates, and some
studies suggest that it increases diagnostic sensitivity and specificity (Castro et al.
2005; Carmeci et al. 1998; Danese et al. 1998). The FNAB cytological diagnosis of
papillary thyroid cancer is usually highly dependable, while it is difficult to
demonstrate malignancy or not for the founding of follicular lesions, because it
requires histological examination in order to evaluate infiltration of the tumor capsule
or vessels.
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TSH is well known for its role in the administration of thyroid functions such as
secretion of thyroid hormones, gland growth, and maintenance of thyroid-specific
gene expression (differentiation). Experimental studies and clinical data have given
evidence that thyroid-cell proliferation is dependent on TSH and that
well-differentiated thyroid cancers express TSH receptors (Stocker et al. 2003; Shi et
al. 1993), and usually keep up responsiveness to TSH. Although oncogenes and other
growth factors are also involved in thyroid cancer growth and development (Derwahl
et al. 1998; Mazzaferri 2000), it seems likely that TSH can act as a cancer stimulus.
These findings provide the fundamental for TSH suppression as a treatment for
differentiated thyroid cancer (Biondi et al. 2005). Several reports have shown that
therapy with suppressive doses of thyroxine (T4) definitely affects outcomes in
differentiated thyroid cancer, resulting in decreased disease progression, recurrence
rates, and cancer-related mortality (Mazzaferri & Jhiang 1994, Mazzaferri 1999, Sipos
& Mazzaferri 2008). Retrospective studies have indicated that TSH suppression is an
independent predictor of recurrence of differentiated thyroid cancer (Pujol et al. 1996),
and prospective studies have shown that aggressive TSH suppression can result in
reductions in thyroid carcinoma-related death and relapse, especially in high-risk
patients (Jonklaas et al. 2006; Hovens et al. 2007). Based on these findings, it is
plausible that the higher rates of malignancy with increasing serum TSH
concentrations reflect an effect of TSH on thyroid tissue promoting neoplasia and
carcinogenesis. Iodine deficiency causes a reduction in the value of circulating thyroid
hormones associated with a resulting rise in serum TSH concentrations, and chronic
12
iodine deficiency is a well-established risk factor for the development of goiter and
follicular thyroid carcinoma (Belfiore et al. 1992, Franceschi 1998, Lind et al. 1998,
Feldt-Rasmussen 2001, Nagataki & Nystrom 2002).
Recently it has been reported that in patients with nodular thyroid diseases, the
risk of malignancy increases with serum TSH concentrations and, even within normal
ranges, higher TSH values are associated with an expressively greater possibility of
thyroid cancer (Boelaert et al. 2006, Jonklaas et al. 2008, Polyzos et al. 2008). Higher
TSH levels have also been associated with advanced stage thyroid cancer and it has
been suggested that TSH may play a central role in its development and progression
(Haymart et al. 2008b). However, in some of these studies (Boelaert et al. 2006,
Polyzos et al. 2008) different thyroid malignancies were grouped, including medullary
or anaplastic cancers or thyroid lymphomas, that have never been reported to be TSH
dependent.
This study set out to further confirm the hypothesis that TSH, a known thyroid
growth factor, may have a fundamental role in thyroid cancer development, and
explore the association between preoperative TSH and differentiated thyroid cancer
(DTC). Additionally this study performed a detailed investigation in which simple
clinical or biochemical parameters might predict the likelihood of thyroid malignancy
in patients presenting with thyroid nodules, thereby identifying those with greater
risks of harboring thyroid malignancy. The study also used these parameters to derive
a formula to predict the risk of diagnosis of malignancy in individual subjects.
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In addition, the finding of higher TSH and increased thyroid cancer incidence
may also be explained by age (Haymart et al. 2008; Boelaert et al. 2006). Given that
there is a rise in TSH with age in the healthy adult population (Surks et al. 2007;
Hollowell et al. 2002) and an increased incidence of microcarcinomas in patients over
age 45 (Miccoli et al. 2008), it is not certain whether the correlation between higher
TSH and thyroid cancer is secondary to advanced age or TSH itself. Thus with the
aim of illustrating the relationship between higher TSH and thyroid cancer, the study
also have an analysis to examine the relationship between TSH, age and thyroid
cancer.
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Part I THEASSOCIATION BETWEEN SERUM TSH
CONCENTRATIONAND DIFFERENCIATED THYROID
CANCER
SUBJECTSAND METHODS
Subjects and data recorded
During the years 2012–2014, 9774 patients underwent thyroid surgery at our
department. Demographic and pathologic data from the 1287 patients with
preoperative serum TSH concentration and either benign thyroid nodules or DTC
were recorded. Data were extracted from the department’s patient files. TSH levels
were obtained within 2 months before surgery and these levels were analyzed in
relationship to DTC on postoperative pathology. The cohort included 1048 females
and 239 males with a mean age of 49.2±13.2 yr (range 6-78 yr). The criteria for
patients included in the cohort were as following:
1. They had the presentation of a solitary thyroid nodule or at least one dominant
thyroid nodule within a multinodular goiter, detected by clinical examination,
ultrasound or both.
2. They had at least one diagnostic cytological result by FNAB (patients with
non-diagnostic cytology were excluded).
3. They were not taking L-T4 or methimazole treatment and were clinically and
biochemically euthyroid [defined as normal serum concentrations of free T4 (FT4)
and free T3 (FT3)].
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4. They had TSH, free thyroid hormones, and anti-thyroid antibodies measured
simultaneously with FNAB.
5. The patients with diagnosis of Graves’ disease and Hashimoto’s thyroiditis had
been excluded. The diagnosis of nodular Hashimotos’ thyroiditis was made if they
showed a diffused hypoechoic ‘thyroiditis’ pattern at thyroid ultrasound and had high
levels of anti-thyroperoxidase (TPOAb) and/or anti-thyroglobulin (TgAb) antibodies.
Patients were defined as Graves’ disease according to usual standard criteria including
hyperthyroidism, goiter with diffused hypoechoic pattern at thyroid ultrasound,
ophthalmopathy, and serum positive for anti-TSH receptor antibodies, and/or TgAb or
TPOAb.
The final diagnostic outcomes were the presence or absence of DTC on final
pathology. With age, gender, nodule number, nodule size, preoperative fine-needle
aspiration biopsy (FNAB), serum TSH as continuous variables, TSH within
designated ranges were assessed in relationship to the postoperative pathological
outcomes. The following analysis evaluates TSH as the dependent variable; variables
such as gender, age, nodule size, nodule number, and cancer were examined in
relation to TSH.
All patients gave their informed consent to the study.
Thyroid profiles tests
Serum free triiodothyronine (FT3) and free thyroxine (FT4) were measured by
RIA (FT3 by Liso-Phase kit – normal values K 2.7–5.7 pg/ml; FT4 by Liso-Phase kit
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– normal values 7–17 pg/ml; Technogenetics, s.r.l., Milan, Italy). Serum TSH was
measured by a sensitive immunoradiometric assay (Delphia Pharmacia, Turku,
Finland – normal values 0.4–3.4 μU/ml). TPOAb and TgAb were measured by an
immunoenzymatic assay (AIA-Pack TgAb, and TPOAb, Tosoh,Tokyo, Japan).
Normal values were<10 U/ml for TPOAb and <30 U/ml for TgAb.
Cytological and histological diagnosis
FNAB was performed under ultrasound guidance using a 23-gauge needle
attached to a 10 ml syringe. The material was air-dried, stained with Papanicolaou and
Giemsa and interpreted by an experienced cytologist. The adequacy of aspirates was
defined according to the guidelines of the Papanicolaou Society (The Papanicolaou
Society of Cytopathology Task Force on Standards of Practice 1996) .
According to accepted guidelines of British Thyroid Association (2007),
cytological findings were classified as: (1) non-diagnostic (Thy1 category according
to BTA guidelines); (2) benign (BTA Thy2, non-neoplastic category); (3)
indeterminate [including BTA categories Thy3 (follicular lesions) and Thy4
(suspicious of malignancy)]; and (4) diagnostic of malignancy (BTA Thy5 category).
Patients were assigned to a final diagnostic category for cytology diagnosis (true
negative, true positive, false negative, or false positive for malignancy) according to
postoperative formal histological results. The cytological diagnosis was defined true
negative if a diagnosis of thyroid malignancy had not been made after surgery.
Cytological indeterminate or malignant finding was considered true positive if
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malignancy was confirmed by histological results. Cytological results were
considered as false negative in subjects whose FNAB had one or more diagnostic
results without suspicious or malignant features in whom later surgery provided
evidence for malignancy (including those patients harboring a microcarcinoma).
For postoperative histological diagnosis, formalin-fixed, paraffinembedded
nodular tissues were stained by hematoxylin and eosin. The diagnosis was made
blindly by two independent pathologists, according to the guidelines of World Health
Organization. When the results were discordant, agreement was found by conjoint
re-examination of each case. The histological results following surgery were classified
as benign or malignant. In patients with DTC, cancer was staged according to the
TNM classification (Sobin 2002).
Operation
There were predominantly five surgeons performing thyroid surgeries during this
period. Of the 1287 thyroid surgeries, 267 underwent unilateral resection and 1020
underwent total thyroidectomy. Unilateral resections were primarily performed for (1)
small single follicular lesions; (2) benign nodules locating within unilateral thyroid
loble. Total thyroidectomies were primarily performed for (1) malignant or
indeterminate cytology; (2) large compressive benign nodules; (3) benign cytology
but clinical suspicion of malignancy or patient’s request for cosmetic reasons.
Classification
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According to clinical findings, ultrasound examination and/or thyroid
scintigraphy patients were subdivided into two diagnostic groups. (1) The patients
with isolate thyroid nodule had a single, cold nodule. (2) The multinodular goiter
(MNG) patients presented a goiter with multiple nodules. At thyroid scan they had
only cold nodules or both cold and ‘hot’ nodules. In these patients, FNAB was
performed only on cold thyroid nodules.
Patients were classified into six groups according to their serum TSH
concentration: subclinical hyperthyroidism [TSH < 0.4 (group 1)], subclinical
hypothyroidism [TSH > 3.4 (group 6)], and patients with TSH concentration within
the normal range were subdivided into four quartiles of similar size [TSH 0.4–0.59
mU/ml (group 2); TSH0.60–0.89mU/ml (group 3); TSH 0.9–1.59 mU/ml (group 4);
TSH 1.60–3.4mU/ml (group 5)].
The histological results following resection were classified as benign or
malignant. In patients with DTC, cancer was staged according to the TNM
classification (Sobin 2002):
(1) Patients younger than 45:
Stage I (any T, any N, M0): The tumor can be any size (any T) and may or may
not have spread to nearby lymph nodes (any N). It has not spread to distant sites (M0).
Stage II (any T, any N, M1): The tumor can be any size (any T) and may or may
not have spread to nearby lymph nodes (any N). It has spread to distant sites (M1).
(2) Patients 45 years and older:
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Stage I (T1, N0, M0): The tumor is 2 cm or less across and has not grown outside
the thyroid (T1). It has not spread to nearby lymph nodes (N0) or distant sites (M0).
Stage II (T2, N0, M0): The tumor is more than 2 cm but not larger than 4 cm
across and has not grown outside the thyroid (T2). It has not spread to nearby lymph
nodes (N0) or distant sites (M0).
Stage III: One of the following applies:
T3, N0, M0: The tumor is larger than 4 cm across or has grown slightly outside
the thyroid (T3), but it has not spread to nearby lymph nodes (N0) or distant sites
(M0).
T1 to T3, N1a, M0: The tumor is any size and may have grown slightly outside
the thyroid (T1 to T3). It has spread to lymph nodes around the thyroid in the neck
(N1a) but not to other lymph nodes or to distant sites (M0).
Stage IVA: One of the following applies:
T4a, any N, M0: The tumor is any size and has grown beyond the thyroid gland
and into nearby tissues of the neck (T4a). It might or might not have spread to nearby
lymph nodes (any N). It has not spread to distant sites (M0).
T1 to T3, N1b, M0: The tumor is any size and might have grown slightly outside
the thyroid gland (T1 to T3). It has spread to certain lymph nodes in the neck (cervical
nodes) or to lymph nodes in the upper chest (superior mediastinal nodes) or behind
the throat (retropharyngeal nodes) (N1b), but it has not spread to distant sites (M0).
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Stage IVB (T4b, any N, M0): The tumor is any size and has grown either back
toward the spine or into nearby large blood vessels (T4b). It might or might not have
spread to nearby lymph nodes (any N), but it has not spread to distant sites (M0).
Stage IVC (any T, any N, M1): The tumor is any size and might or might not
have grown outside the thyroid (any T). It might or might not have spread to nearby
lymph nodes (any N). It has spread to distant sites (M1).
According to age, patients were divided into some subgroups. Age was
categorically evaluated within age ranging < 45 vs. ≥45 years and then < 30, 30–44,
45–59 and ≥ 60 years. The age 45 was used as a cut-off for the same extent of disease
results in worse prognosis in patients ≥45 years comparing < 45 years. The categories
of age ranging < 30 and ≥ 60 years were used because the likelihood of cancer is
higher in patients less than age 30 or older than 60 years.
Statistical analysis
SPSS 1.3 for Windows (SPSS Inc., IL, USA) is used for statistical analysis. Data
are presented as mean ± standard deviation (SD) or percentage. Numeric variables
with skewed distribution were identified by using the Kolmogorov–Smirnov test and
accordingly nonparametric tests were used. For numeric variables, the student’s t test
or Mann–Whitney tests were used. The chi-square test (X2) or Fisher’s exact test were
used for categorical variables. Four fold tables(2 × 2) were built to calculate
sensitivity (true-positive results divided by true-positive plus false-negative results),
specificity (true-negative results divided by true negative plus false-positive results),
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positive predictive value (PPV) (true-positive results divided by true-positive plus
false-positive results) and negative predictive value (NPV) (true-negative results
divided by true-negative plus false-negative results) of FNAB cytological results
compared with histological results. The “Cohen’s Kappa” was used to calculate the
degree of agreement between cytological and histological results. A value of 0
indicates that agreement is no better than chance whereas a value of 1 indicates a
perfect agreement. Binary logistic regression analysis was used to evaluate the
independent influence of factors including age, gender, nodule type (solitary or
multinodule), serum TSH concentration and presence of anti-thyroid antibodies at
presentation on the final diagnostic outcome. In this analysis age and TSH
concentration were used as categorical variables. Furthermore, through binary logistic
regression analysis a formula was proposed to predict the likelihood of malignancy in
an individual patient using the serum TSH concentration as a continuous variable.
Another multivariate analysis was tested to evaluate TSH as the dependent variable
instead of cancer. Univariate and multivariate analyses both were used to determine
the relationship between age and cancer with respect to higher TSH concentration.
A P value less than 0.05 was considered to be statistically significant in all the
above analyses.
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RESULTS
Patient and tumor characteristics
For the final histological results after surgery, 1064(82.7%) patients had benign
nodules and 223(17.3%) patients had malignant diseases. Papillary thyroid cancer
(PTC) comprised 93% of all thyroid malignancies (207 of 223). Seven percent of
thyroid malignancies (16 of 223) were follicular thyroid cancer (FTC) or Hurthle cell
cancer. Because the medullary thyroid cancer, anaplastic thyroid cancer, and
lymphoma were considered unlikely to be TSH responsive, they were not included in
the analysis.
A disproportionate number of women underwent thyroid surgery for both benign
and malignant diseases relative to men. Especially in women, the overwhelming
number of these surgeries were for benign causes. Of the 1048 female patients, 163
(15.6%) had malignancy on final pathology vs. 60 of the 239 male patients (25.1%)
(P=0.001).
In addition, patients with malignancy were significantly younger than those with
benign. Mean age of the patients with malignancy was 45±0.5 yr and the mean age of
whose without malignancy was 52±0.6 yr (P=0.008).
In those patients with DTC, mean nodule size was 2.2±0.3 cm compared with
3.6±0.05 cm in those with benign nodules (P=0.0001). All patients had their thyroid
assessed by ultrasound prior to their surgery, and 835 (65.0%) were found to have
multiple nodules, whereas 452 (35.0%) had a solitary thyroid nodule. Patients with a
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solitary nodule on ultrasound had significantly higher rates of malignancy (n=126,
27.9%) when compared with those with multiple nodules (n=97, 11.6%, P=0.009). So
there was an association between solitary vs. multiple nodules and likelihood of DTC.
(Table 1-1)
FNAB cytology and histological validation
If indeterminate cytological results are considered as potential malignant and
histological results as the “gold standard” for the diagnosis, on the whole, 387/1287
(30.1%) patients who had FNAB cytology indeterminate or malignant and 900/1287
(69.9%) who had one or more cytological benign thyroid nodules were included in the
benign group. According to the histological results after surgery, the soundness of
FNAB cytological diagnosis in these patients was evaluated. The histological
diagnosis of DTC was confirmed in 205/387 (52.9%) patients with a cytology
indeterminate or indicative of malignancy and was found in 18/900 (2.0%) patients
with cytological diagnosis of benign nodules. A true-negative cytological diagnosis
was made in 882 (68.5%) patients. Only one of 182 (14.1%) patients with a
false-positive result had a previously cytological diagnosis of malignancy, the
remainders were having indeterminate cytological aspirates including follicular
lesions in 165, suspicious of malignancy in 16. (Table 1-2)
Review of the initial cytology in this group did not indicate an error of
interpretation in any case, and false-negative cytology results were therefore likely to
reflect sampling error. The final histological diagnosis for the 18 patients in this
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false-negative group was follicular carcinoma in 9, papillary carcinoma in 7, and
Hurthle cell carcinoma in 2 subjects. One of those with false-negative cytological
diagnosis harbored a microcarcinoma.
Thus, FNAB cytology had an elevated specificity (91.9%) and sensitivity (82.9%).
In the study, the positive predictive value (PPV) of cytology was 52.9% and the
negative predictive value (NPV) was 98.0%. The degree of agreement between
cytological and histological results as defined by the “Cohen’s Kappa” was
statistically significant (Kappa=0.62, P < 0.001).
Free thyroid hormones and TSH values in BTND and PTC patients
As shown in Table 1-3, serum TSH levels in DTC patients (mean 1.20 ±0.1uU/ml)
were significantly higher than in BTND patients (mean 0.80 ±0.3uU/ml). In contrast
to the finding observed with TSH levels, serum FT3 and FT4 levels were not
significantly different in BTND and DTC.
When the subgroup of patients with FNAB indeterminate (Thy3, Thy4)
cytological results was analyzed, there was also a similar trend for higher TSH with
malignancy vs. benign pathology. In the 103 patients with malignancy on final
pathology of this subgroup, mean TSH was 1.6±0.4 vs. 0.9±0.6uU/ml in the 181
patients with benign pathology (P=0.06) (Table 1-3).
Prevalence of DTC according to serum TSH levels
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In the whole group of patients, 255/1287 (19.8%) had subclinical
hyperthyroidism, i.e. serum TSH concentrations below 0.4 uU/ml with normal serum
free thyroid hormone concentrations. 34 patients with thyroid nodular had subclinical
hypothyroidism, i.e. serum TSH levels slightly higher than normal range. Totally 998
patients had serum TSH levels within the normal range. These patients were
subdivided into four quartiles of similar size according to their TSH values. The
prevalence of DTC according to serum TSH levels is shown in Fig. 1-1.
The frequency of DTC was higher in patients with higher TSH values. The lowest
two groups in patients are group 1 with subnormal TSH values (6/255; 2.4%) and
group 2 (5/243; 2.1%) with TSH values between 0.40-0.59 uU/ml. The highest
frequency is in patient group 5 with TSH values between 1.6 and 3.4 uU/ml (19/209;
9.2%). It is worth underlining that in patients with TSH greater than 3.4 uU/ml the
frequency of DTC (3/34; 8.1%) was not significantly different from patients with TSH
in the upper quartile of normal range (1.60–3.4uU/ml) (P=0.1).
Again, the above analysis was repeated in the subgroup of patients whose FNAB
cytological results were indeterminate (Thy3, Thy4, n=284), and the same trend of
escalating cancer incidence with higher TSH levels persisted. (Fig.1-1)
TSH values and cancer stage
Patients with DTC were staged according to tumor node metastasis (TNM) and
results are shown in Table 1-4. An overwhelming number of subjects had stage I and
II DTC (190 of 223). Only 15% (33 of 223) of patients had stage III and IV DTC. The
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patients with advanced disease (stage III and IV) had a significantly higher mean TSH
level relative to those with stage I and II. The mean TSH of those with advanced
disease was 2.8 ±1.6 vs. 0.74±0.3 uU/ml (P=0.003). Of the 33 patients with advanced
DTC, 21 patients had TSH levels above the mean population TSH of 0.9 uU/ml vs.
only 12 had TSH levels less than 0.9 uU/ml.
TSH value according to the presence of TAb
To explore the possible effect of thyroid autoimmunity on TSH values, this study
also analyzed TSH levels according to the presence of TAbs. The percent of
malignancy was significantly higher (12.4 vs. 6.3%, P=0.02) in patients with
detectable thyroid antibodies, compared with those in whom antibodies were absent
(n=1119). (Table 1-5)
In TAb positive subjects TSH (0.80±o.3 uU/ml) was significantly higher
(P=0.002) than in TAb negative patients (0.60±0.5 mU/m), accounting for the
significant statistical difference observed between these two groups. (Fig. 1-2) Both in
TAb positive and negative patients, serum TSH levels were significantly higher in
DTC than in BTND group (Fig. 1-3). In TAb positive group the mean level of TSH
was 1.30±0.7 mU/ml in DTC and 0.70±0.1 mU/ml in BTND (P<0.0001). However in
TAb negative patients, the mean level of TSH was 1.10±0.08 uU/ml in DTC and
0.60±0.3 mU/ml in BTND (P<0.0001). However logistic regression analysis,
simultaneously analyzing the serum TSH concentration and the presence of antibodies,
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did not identify thyroid antibody status to be an independent predictor of thyroid
malignancy (adjusted odds ratio 1.19, 95% confidence interval 0.6 –2.35, P =0.6).
Patient and tumor characteristics based on age
Patients younger than age 45 differed significantly from those aged 45 and above
in many categories. The younger patients were more likely to have DTC, a smaller
and solitary nodule. Surgical patients under age 45 had a 22% (114/517) incidence of
malignancy vs. those ≥ 45 who had a 14% (109/770) frequency of DTC (P=0.004).
The primary nodule resulting in surgery was 2.4 ± 0.02 cm in the younger patients vs.
2.8 ± 0.01 cm in the older subset (P=0.006). On ultrasound exam, multiple nodules
were detected in 328/517 (63%) of the patients aged < 45 vs. 507/770 (66%) of those
≥ 45 (P=0.013). Mean TSH level was also substantially higher in older patients vs.
younger. In patients aged ≥ 45, mean TSH was 1.64 ± 0.24 uU/ml and in patients aged
< 45, mean TSH was 0.72 ± 0.11 uU/ml (P=0.017). Even the ratio of male to female
differed in those patients over age 45 vs. less than 45. There were 71/517 (14%) male
patients in the younger group vs. 168/770 (22%) male patients in the older group.
(Table 1-6)
Prevalence of DTC and TSH values based on age
There were 64 patients in the age group < 30 years, 11 of whom with malignancy.
There were 453 patients in the age group 30–44 year, 58 of whom with malignancy.
There were 451 patients in the 45–59 year age group, 50 of whom with malignancy.
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In the age group ≥ 60 years, there were 319 patients, among whom 104 had cancer.
The change in prevalence of DTC according to age was not linear and higher
prevalence was observed at both extremes of age (Fig. 1-4). Although there was a
trend towards higher rates of DTC in patients who were younger than 30 years or
older than 60 years at presentation, the difference was statistically significant only
between groups 45–59 and over 60 years (P= 0.022). Thus the study incorporated an
age squared term in the binary logistic regression analysis to correct this increased
rates of DTC in patients younger than 30 yr and older than 60 yr at the time of
presentation.
In both age groups < 45 years and ≥45 years (Fig. 1-5), mean TSH was
significantly higher in patients with DTC compared with those with BTND (P =0.045
and 0.028, respectively). When the patients were further divided by age < 30, 30–44,
45–59 and ≥60 years, there was not a significant trend towards a rise in TSH level
with age in the BTND subgroups and a parallel but more rapid increase in TSH in the
groups with DTC (Fig. 1-6). The difference between DTC vs. BTND within each
subgroup was statistically significant in those aged 30–44 and 45–59 years (P=0.038
and 0.034, respectively). The mean TSH was consistently within the normal range,
although it was higher in the cancer subgroups.
In multivariate analysis including age, gender, nodule size, nodule number, and
thyroid cancer, higher TSH had only independently a significant association with
thyroid cancer incidence (P=0.033). Although there was a trend for an association
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between higher TSH and advanced age, this trend was not statistical (P=0.458) (Table
1-7).
Independent risk predictors for DTC
The logistic regression analysis was performed, simultaneously analyzing
gender, age, nodule type, nodule size and TSH level in which factors could be
considered as independent risk predictors for DTC. As shown in Table 1-8,
significantly increased adjusted odds ratios for malignancy were detected in male
patients, younger age, solitary nodules, smaller nodules and serum TSH above 0.59
uU/ml. The square of the age was also taken into account in the calculations to correct
the increased risk in patients of age younger than 30 or older than 60 yr. A
simultaneous likelihood ratio test of the effect of all these factors gives X2=47.6
(P<0.001), indicating the combination of these factors in the prediction of malignancy
to be very valuable.
Based on the independent risk factors identified from the binary logistic
regression analysis, this study calculated formulae to predict the risk of thyroid cancer
from simple clinical and laboratory markers in individual patients. These calculations
were based on the patients who had their TSH concentration measured in a sensitive
assay; the adjusted odds ratios analyzing serum TSH as a categorical variable
suggested that TSH could be satisfactorily used as a continuous variable in these
formulae. The risk of malignancy was calculated through the formula: P=1/(1＋e-x),
with e representing the antilogarithmic transformation (e=2.71828) and x being a
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calculation taking into account the patient’s age and gender, the nodule type, and TSH
level. For the probability of malignancy, a numeric x was obtained by following
calculation: x=2.357 ＋ 1.036 (type) -0.064 (size) -0.558 (gender) -0.072 (age)
+0.00163 (age2)+0.426 (TSH concentration). The nodule type was coded as 1 for
multinodular goiter and 2 for solitary nodule. The patient’s gender was represented by
1 for males and 2 for females.
31
DISCUSSION
Reliability of FNAB
The FNAB has been reported to have a sensitivity ranging between 65 and 98%
and specificity ranging between 72 and 100%. These variations reflect how the
indeterminate or suspicious cytological results were entered into the calculations
(Gharib and Goellner 1993). Diagnostic FNAB results are acquired in approximately
80% of the cases and repeating aspiration can improve the accuracy of the procedure
(Castro and Gharib 2005; Chow et al. 2001; Gharib and Goellner 1993). In our series,
acceptable sensitivity, specificity, NPV, and PPV have been achieved. The sensitivity
(82.9%) and specificity (91.9%) of FNAB as well as the low false-negative rate for
the diagnosis of malignancy (2.0%) in this cohort compare favorably with other large
series (Gharib et al. 1993; Hamburger 1994; Hegedus 2004). In the indeterminate
cytological results, 103 of the 284 patients (45.8%) proved to have a carcinoma
(papillary in forty cases, Hürthle cell in eight cases, follicular in fifty five case),
whereas 181 had benign histological results. This ratio seems to be higher than that
reported in previous studies (Block et al. 1983; Gharib et al. 1984). Due to in this
study follicular lesions and suspect malignant were considered as potential cancer,
223 (17.3%) were DTC vs. approximately 30% of FNAB patients. In the 182 patients
who were confirmed benign thyroid nodules by surgery with FNAB indeterminate, a
majority of follicular lesions (165) were found. This part of patients may avert
unnecessary resection.
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In addition, the rate of nondiagnostic FNAB samples (6.2% after repeated
biopsies) was reported by previous studies as between 5 and 20% (Gharib et al. 1993,
Carmeci et al. 1998, Danese et al. 1998). In one study, 4 of the 20 patients (20%) with
persistent had a carcinoma (papillary in three cases and follicular in one), whereas 16
had benign histological results. This finding is in accordance with previous studies,
which have reported that a non-diagnostic FNAB may be associated with a high
probability of thyroid malignancy and it should not be considered benign (Chow et al.
2001).
The cytological diagnosis of PTC is usually highly dependable, while the
diagnosis of follicular thyroid cancer is indeterminable for requiring histological
examination in order to evaluate infiltration of the tumor capsule or vessels.
Management of patients with FNAB follicular lesions or being suspicious for
malignancy is not as straightforward as management when aspirates are clearly
benign or malignant. In this study, TSH was an independent predictor of DTC on
univariate and multivariable analysis, and this predictive value persisted when TSH
was subdivided into ranges. In the subset of patients with FNAB cytology Thy3
(follicular lesions) and Thy4 (suspicious of malignancy), there was a similar trend
toward improved rate of DTC with higher TSH level. Larger sample sizes are needed,
but if high TSH level is predictive of DTC especially follicular thyroid cancer when
aspirates are follicular and suspicious for malignancy but not sure, TSH could play a
key role in determining optimal surgical intervention.
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The association between TSH and DTC
This study confirms that there was a significant difference between serum TSH
levels in patients with DTC and BTND, and that the risk of malignancy in thyroid
nodules increased with serum TSH concentration even within the normal range. An
increased risk of DTC was found in a TSH level above the population mean relative
to below the mean within normal range TSH. Serum TSH concentration at
presentation is an independent predictor of thyroid malignancy in euthyroid patients
presenting with thyroid nodules. Well-differentiated thyroid cancers express the
TSH-receptor on their cell membranes and usually retain responsiveness to TSH. For
this reason TSH suppression therapy with L-T4 plays an important role in its
treatment (Mazzaferri & Young 1981, Mazzaferri 1991, 1999, Mazzaferri & Jhiang
1994, Biondi et al. 2005, Sipos & Mazzaferri 2008).
TSH has a trophic effect on thyroid carcinoma growth, which is likely to be
mediated by TSH receptors (Carayon et al. 1980; Chang et al. 1988). Animal data
demonstrated that TSH suppression in rats exposed to radioactive iodine prevents the
formation of thyroid cancer (Goldberg et al. 1964). However, there are no data in
humans that prove a protective effect of TSH suppression on oncogenesis (Ross 2006).
Nevertheless, thyroxine therapy for TSH suppression after thyroidectomy for
differentiated thyroid carcinomas is independently associated with reduced recurrence
and mortality (Pujol et al. 1996). This nutritional effect of TSH on thyroid tissue that
promotes neoplasia and carcinogenesis could be a possible explanation for the
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increased risk of malignancy associated with serum TSH concentrations in the upper
quartile of the normal range.
Three previous studies attempted to assess TSH as a predictor of thyroid cancer.
The initial two studies analyzed TSH values below normal vs. within normal range. In
the first study, a nonsignificant trend toward decreased cancer risk was found if TSH
was below normal range (Kumar et al. 1999). However in the second study, there was
a significant reduction in risk of cancer if TSH level was below normal range (Lim
AKP et al. 1998). Boelaert et al. published the third study (Boelaert er al. 2006),
which was an analysis of a cohort of 1500 patients who underwent FNAB between
1984 and 2002. This analysis found increased odds rate of malignancy in those
patients with solitary nodules and TSH greater than 0.9 mIU/liter. Although there was
a trend toward increased DTC risk with rising TSH range, no significant difference
existed between normal TSH levels above 0.9 mIU/liter due to the small number of
malignancies (n=120). All these three studies were performed in the United Kingdom
and the incidence of FTC relative to PTC was higher than what would be anticipated
for a U.S. population. In the study by Boelaert et al., 37% of cases were either FTC or
Hurthle cell cancer, while PTC comprised 52% of the cases. This is much lower than
the 88% prevalence of PTC in the United States (Davies et al. 2006). It is not clear
whether this reduced PTC incidence and raised FTC incidence is related to dietary
iodine consumption. It also confuses the association between TSH and malignancy,
given the unknown urinary iodine status. In our study, 93% incidence of PTC and 7%
incidence of FTC or Hurthle cell cancer were similar to the distribution found by the
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Surveillance, Epidemiology, and End Results program (Davies et al. 2006). In
addition, final pathology was available thus confirming or refuting any benign or
malignant FNAB.
Taken together, the study further demonstrated that TSH levels are slightly, but
significantly higher in DTC compared with benign thyroid diseases and that the risk
of malignancy increases in parallel with the serum TSH concentration at presentation
in euthyroid patients, being the highest in patients with serum TSH in the upper limit
of the normal range, which is in agreement with other previously published data.
These findings suggest that serum TSH concentrations can be used as a diagnostic
adjunct in the identification of high-risk patients who require further investigation
and/or surgical intervention.
TSH and autonomous
Thyroid nodules with autonomous function are less likely to harbor malignancy
(Hegedus et al. 2003, Hegedus 2004). In accordance with this, Boelaert et al. and
others (Haymart et al. 2008a, Polyzos et al. 2008) found the lower rates of thyroid
malignancy in those with TSH concentrations below the normal reference range,
suggestive of the presence of thyroid autonomy (Ross 2006). This phenomenon is also
found in this study. The lower cancer incidence may be explained by the findings that
the constitutive activating mutations of the TSH receptors, frequently found in these
autonomous nodules, drive the cAMP pathways through Gsα and very rarely the
cancer-associated Ras-dependent MAPK pathway through Gβγ and
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phosphatidylinositol 3-kinase-γ (Du Villard et al. 2000). Fiore et al. (2009) propose
that the finding of higher serum TSH in patients with malignant thyroid disease is
mainly related to a reduction of serum TSH in those with nodular goiter rather than an
increase in TSH in subjects with PTC.
Ngan et al. (2009) have found germline mutation TTF1 gene in a subgroup of
patients with MNG, and that mutations of this gene are not present in patients without
history of MNG and in healthy subjects. In addition, Gudmundsson et al. (2009) have
shown that variants on specific loci (9q22.33 and 14q13.3) are associated with
increased risk of papillary and follicular thyroid cancer and both alleles are associated
with lower TSH levels in the general population. Interestingly, the gene located at the
14q13.3 locus is TTF1. These observations suggest that a different genetic
background may be present in DTC patients with MNG and that specific mutations
may allow PTC to grow in patients with low serum TSH levels. In the study of Fiore
et al. 2009 the prevalence of DTC in patients with serum TSH<0.4 uU/ml was
significantly lower than in patients with no evidence of thyroid autonomy in MNG,
but in patients with single nodule, a definitive conclusion has not been drawn. They
hypothesize that the development of thyroid autonomy, by reducing TSH levels,
reduces the probability that mutated oncogenes may cause cancer clinically detectable.
It is thus possible to hypothesize that the development of thyroid autonomy, by
reducing TSH levels, may represent a form of ‘selftreatment’.
Although autonomous functioning nodules are less likely to have malignancy
because of this selective pathway activation, this does not explain the escalating
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cancer risk within euthyroid and hypothyroid TSH range. With hyperfunctioning
nodules and positive antithyroid antibodies unable to fully explain the pattern of
elevated thyroid cancer risk with higher TSH, it may suggest that TSH itself is the
unifying variable.
The relationship between TSH and DTC stage
Shown in this study, higher TSH was associated with not only incidence of DTC
but also advanced stage of DTC, confirming the demonstration of Haymart er al.
(2008). Although all of the mean TSH levels fall within the accepted normal range
(0.4–3.4 uU/ml), the mean TSH for benign thyroid disease was 0.80±0.3 vs. 0.74±0.3
uU/ml for stage I and II disease vs. 2.80±1.6 uU/ml for stage III and IV disease. Fiore
et al. also confirm the finding of higher TSH in patients with T3-T4 stage compared
with T1-T2, and median TSH levels were higher in patients with lymph metastases
than those without. Although the absolute number with advanced DTC was small (33
of 223), this escalating risk of advanced disease with higher TSH level suggests TSH
is involved in the pathogenesis of thyroid cancer.
Unique among all malignancies, the staging systems for well-differentiated
thyroid cancer includes age as a key prognostic factor. In this study, it is found that
serum TSH conversation is independent of age and further confirms an association
between advanced stage disease and higher TSH levels.
Autoimmune thyroid disease and thyroid cancer
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In this work, the relationship between the presence of serum thyroid
autoimmunity and TSH levels in patients with DTC have been also analyzed. Several
studies have investigated the relationship between thyroid autoimmunity and
differentiated thyroid cancer, but its meaning is still uncertain (Dailey et al. 1955,
Hirabayashi & Lindsay 1965, Holm et al. 1985, Walker & Paloyan 1990, Baker 1995,
Okayasu et al. 1995).
Although not all studies are in agreement, a meta-analysis of ten studies showed a
2.77-fold increased incidence of thyroid cancer in patients with antibody evidence of
Hashimoto’s thyroiditis, compared with control populations (Singh et al. 1999).
Similar to the Hashimoto’s controversy, there is great debate over the association
between Graves’ disease and thyroid cancer incidence and aggressiveness (Filetti et al.
1988, Hales et al. 1992, Pellegriti et al. 1998, Yano et al. 2007). Because Hashimoto’s
thyroiditis is often associated with progression to hypothyroidism and thus elevates
serum TSH concentration and because TSH receptor stimulation is crucial to the
pathogenesis of Graves’ disease, it is possible that thyroid autoimmunity is linked to
thyroid cancer through the TSH receptor.
This study found significantly higher rates of cancer in patients with detectable
thyroid peroxidase antibodies compared with those in whom antibodies were absent,
although antibody status was not an independent predictor of malignancy. In addition,
Haymart et al. (2008) studying a large histological series of patients with nodular
thyroid diseases submitted to surgery, have reported a significant association between
pathologic Hashimoto’s thyroiditis and higher TSH levels. In his work, pathologic
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Hashimoto’s thyroiditis was detected in 20.6% of patients with DTC and 19.8% of
patients with benign thyroid diseases (P=0.4). In the study by Fiore et al. (2009), the
frequency of thyroid cancer was not significantly different between antibody-positive
and antibody-negative patients, and higher serum TSH concentration was found in
those with PTC when compared with subjects with benign disease regardless of
antibody Status. Otherwise in accordance with this finding, the data of this study also
show that TSH is significantly higher in TAb positive than in TAb negative patients,
suggesting that TAb positivity is the expression of a mild autoimmunity that may
affect thyroid function. In our series of patients, the frequency of DTC was
significantly higher in TAb positive group than TAb negative patients and serum TSH
levels were significantly higher in DTC than BTND both in TAb positive and negative
patients. On the contrary, results of the study supports the hypothesis that humoral
thyroid autoimmunity does play a significant role in the development of thyroid
cancer.
Taken together, the currently available data do not rule out an association between
autoimmunity and thyroid cancer, but indicate that the mechanism underlying the
relationship between high serum TSH and thyroid cancer are different from that
affecting the link between autoimmune thyroid disease and thyroid cancer. Clearly,
further studies evaluating the role of autoimmune processes in the development and
progression of thyroid cancer are required to support this.
Gender, age, nodule size and type in DTC
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In addition to preoperative TSH being predictive of DTC, male gender, younger
age, smaller and solitary nodule were independent predictors of malignancy. This is
not because men and younger patients have a higher absolute number of malignancies
but because older patients and women have an increased likelihood of surgery for
benign conditions such as resection of benign multinodular goiter with compressive
symptoms. Because women and older patients tend to have a higher TSH (Hollowell
et al. 2002) and women and older patients were overrepresented in the subgroup
undergoing surgery for benign reasons, one female or older patient having anticipated
higher TSH would correlate with benign disease, not malignancy.
An increased risk of underlying malignancy in men compared with women, has
been demonstrated previously (Hegedus et al. 2003, Mazzaferri et al. 1993, Hegedus
et al. 2004), although a few smaller studies indicated patients’ gender are not to be
helpful in predicting risk of carcinoma (McHenry et al. 1993, Raber et al. 2000). A
retrospective case series of 1009 patients evaluating the natural history of
cytologically benign thyroid nodules using ultrasonography indicated that patient’s
gender did not predict nodule growth (Alexander et al. 2003). In our series,
significantly increased rates of malignancy were detected in men, regardless of age,
nodule type, nodule size and serum TSH concentration, and logistic regression
analysis identified patients’ gender as an independent predictor of thyroid malignancy
(adjusted odds ratio 2.42, P <0.0001).
The use of US is advantageous in this study, as US is more accurate than
palpation in differentiating solitary nodules from multiple nodules and it approaches
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the frequency of thyroid nodules found in autopsy studies (Ezzat et al. 1994;
Schneider et al. 1997). Furthermore, almost 50% of the patients referred for a palpable
solitary nodule were found to have multiple nodules on US (Marqusee et al. 2000).
Our results indicate that the presence of a solitary and smaller nodule on US at
presentation was associated with increased malignancy rates, compared with those
patients presenting with multiple nodulars(P < 0.001). Moreover the type of nodule
was identified as an independent predictor of malignancy in the binary logistic
regression analysis after correcting patients’ age and gender. This finding is in
accordance with published previous studies which have indicated increased cancer
risk in nodules deemed solitary by palpation (Hegedus et al. 2003; Franklyn et al.
1993; Hegedus 2004; Tuttle er al. 1998; Mazzaferri et al. 1988; Frates et al. 2006),
although controversy that others have found similar rates of malignancy when
comparing solitary lesions and multinodular goiters still exists over that matter
(Belfiore et al. 1992; McCall et al. 1986; Tollin et al. 2000).
Despite the observation of higher rates of malignancy in ages under 30 and over
70 years in this study, as reported elsewhere (Belfiore et al. 1992; McHenry et al.
1988), the difference was hardly statistically significant. The smaller number of our
patients aged under 30 and over 70 compared with the other age groups in the final
diagnostic outcome might have accounted for this. Multiple population-based studies,
including the National Cancer Database Report and the Surveillance, Epidemiology
and End Results, have shown age to be an important prognostic indicator for
well-differentiated thyroid cancer (WDTC) (Gilliland et al. 1997; Hundahl et al.
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1998). Patients over age 45 can have the same degree of disease but a distinctly
different prognosis than those under age 45. The reason for this discrepancy is not
entirely clear, but it does imply that there is something intrinsic either to the cancer or
to the treatment that is age dependent. As the finding in this study there was an
association between higher TSH and advanced-stage disease. While advanced-stage
disease is age dependent, we wanted to explore whether age, a known prognostic
factor, played a role in this relationship. As illustrated in study, the patient and tumor
characteristics in patients less than age 45 vs. age ≥45 are inherently different. Given
the higher incidence of thyroid nodules in older patients (Tan et al. 1997) as a group,
older patients are more likely to have benign and large nodules. Thus, the increased
incidence of large nodules and surgery for benign nodules in patients aged 45 and
older is not surprising. In addition, the increased likelihood of multiple nodules in
older patients is also expected.
However, despite these marked differences in patient characteristics, the
association between higher TSH and cancer incidence persists in every age group. The
association is only significant in the two groups with the largest number of patients,
aged 30–44 and 45–59 years, but the trend is still present in patients aged<30 and ≥
60 years. The mean TSH in patients aged ≥ 45 years is significantly higher than in
those aged < 45. When we subdivide patients into cancer vs. no cancer, the predictive
value of age weakens. Similar to data from the National Health and Nutrition
Examination Survey (NHANES III) on a healthy population with no known thyroid
disease (Surks et al. 2007), our data from the benign subgroups show a trend for rising
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mean TSH with age. Yet when patients with thyroid cancer are compared with those
with benign nodular disease, cancer patients have a higher mean TSH within every
age group. The mean TSH in the cancer population rises in parallel, but is consistently
higher than the mean TSH in the benign nodular population. These data suggest that
the association between higher TSH and increased thyroid cancer incidence cannot be
explained by age alone. Further supporting the independent relationship between TSH
and thyroid cancer incidence, thyroid cancer, not age, has a significant association
with higher TSH on multivariate analysis.
However the fact that in this patient population, higher TSH value significantly
correlated with increased risk of malignancy is strong evidence that TSH receptor
stimulation is likely involved in the pathogenesis of thyroid cancer. Further population
studies with large sample sizes are needed to confirm this hypothesis.
The thyrotropin receptor in differentiated thyroid cancer
The role of the TSH receptor has been more extensively assessed in benign
nodules. The growth and function of the thyroid are controlled by thyrotropin (Van
Sande et al. 1995) through the activation of its receptor, which belongs to the large
family of G protein-coupled receptors. In spite of the extreme multiplicity of their
ligands, all receptors from this big family have a common molecular architecture:
seven transmembrane segments, three extracellular loops, three intracellular loops, an
extracellular amino terminal, and an intracytoplasmic carboxy terminal. The
subfamily of glycoprotein hormone receptors is characterized mainly by a particularly
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long amino-terminal extracellular domain that confers binding specificity (Van Sande
et al. 1995; Paschke et al. 1996). The thyrotropin receptor is encoded by 10 exons
chromosome 14, with the first nine exons of which encode the large extracellular
domain, and the transmembrane segments and the carboxy terminal are encoded by
exon 10. Though a lot of splice variants of the receptor have been found, their
pathophysiologic importance is not known (Van Sande et al. 1995; Paschke et al. 1996;
Paschke et al. 1995). The thyrotropin receptor is preferentially coupled to the α
subunit of the stimulatory guanine-nucleotide–binding protein (Gsα) that activates
adenylate cyclase and increases the accumulation of cyclic AMP(cAMP). In addition,
insulin-like growth factor I, epidermal growth factor, transforming growth factor b,
platelet-derived growth factor, fibroblast growth factor, and cytokines, mainly acting
by means of the protein tyrosine kinase signal transduction pathway, stimulate the
growth and dedifferentiation of thyroid epithelial cells (Van Sande et al. 1995). Both
the growth and the function of the thyroid are stimulated by cAMP (Van Sande et al.
1995; Dumont et al. 1991). This second messenger indirectly regulates the expression
of the thyroglobulin and thyroid peroxidase genes, whose promoters contain binding
sites for the transcription factors TTF1, TTF2, and PAX8 (Damante et al. 1994). As a
consequence, continued stimulation of the cAMP pathway causes hyperthyroidism
and thyroid hyperplasia. Therefore, if a single thyroid epithelial cell had a somatic
mutation causing chronic stimulation of the cAMP pathway, that cell would acquire a
growth superiority and clonal expansion would account, leading to the formation of
an autonomously functioning thyroid adenoma and ultimately to hyperthyroidism.
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Conversely, inhibition of this cascade by autoantibodies that block the thyrotropin
receptor or by a defective thyrotropin receptor would cause hypothyroidism.
In recent years alterations of the thyrotropin receptor and the regulatory pathways
it controls have been identified in both hyperthyroidism and hypothyroidism. The
demonstration of the oncogenic potential of the cAMP pathway in benign
hyperfunctioning thyroid adenomas prompted investigation of the role of this pathway
in the pathogenesis of differentiated thyroid carcinomas. There are two studies finding
mutations in Gsα in 7 of 61 carcinomas (Suarez et al. 1991; Yoshimoto et al. 1993). In
another two studies, constitutively activating mutations in the thyrotropin-receptor
gene were detected in 5 of 44 carcinomas (Russo et al. 1995; Spambalg et al. 1996),
but not in any of the tumors Gsα mutations were found. All the mutations in the
thyrotropin receptor gene in these tumors had previously been identified in
autonomously functioning adenomas. Constitutive activation of the cAMP pathway in
the thyroid leads to progressive growth of thyrocytes, while usually maintaining cell
differentiation (Dumont et al. 1991). However, the thyroid carcinomas with Gsα
mutations did not take up iodine (Russo et al. 1995), suggesting a second,
dedifferentiating genetic alteration. In agreement with a multistep model of thyroid
carcinogenesis, the presence of a Gsα or a thyrotropin-receptor gene mutation
together with an activated ras gene has been demonstrated in differentiated carcinoma
(Russo et al. 1995). It is therefore likely that both the ras and Gsα or
thyrotropin-receptor gene mutations act synergistically to cause the tumor phenotype
in some differentiated thyroid carcinomas. However, thyrotropin-receptor gene or Gsα
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mutations in differentiated thyroid carcinomas are rare, and chronic activation of the
cAMP pathway probably does not increase the likelihood of further genetic damage,
as suggested by the rarity of malignant transformation in autonomously functioning
thyroid adenomas, Graves’s disease, and the benign toxic thyroid hyperplasia in
transgenic mice with chronic stimulation of the cAMP pathway by ectopic expression
of the adenosine A2 receptor27 or Gsα mutations (Michiels et al. 1994) in the thyroid
gland.
The current research situation and advances in relationship between TSH and
DTC
The pathogenesis behind mean TSH value being elevated in cancer patients is
still unclear.
Although it is still an ongoing debate, some experts conclude that TSH receptor
stimulation is associated with increased cancer incidence and aggressiveness
(Mazzaferri 2000). There are several lines of evidence supporting a correlation
between TSH and thyroid cancer and in favor of the role of TSH receptor in cancer.
Functional TSH receptors were found express on the plasma membrane of both
benign and malignant thyroid tumors (Ichikawa et al. 1976), and vitro studies have
demonstrated that TSH improve adenylate cyclase activity leading to cAMP
production and cell growth through stimulation of these receptors (Carayon et al.
1980, Chang et al. 1988). Differentiated thyroid cancers usually retain responsiveness
to TSH, and suppressive doses of L-T4 taken orally can be used to restrain the
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progression of metastatic thyroid cancer (Balme 1954, Simpson et al. 1988) as well as
to reduce rates of recurrence in patients underwent surgery and radioactive iodine
(Mazzaferri & Jhiang 1994, Mazzaferri 1999, Biondi et al. 2005). A retrospective
study has shown that undetectable TSH values were associated with longer
relapse-free survival and that TSH suppression is an independent predictor of
recurrence (Pujol et al. 1996). Furthermore, suppressive doses of L-T4 increase
overall survival in high-risk patients (Sanders & Cady 1998). Current clinical thyroid
nodule management guidelines highlight the important role for TSH suppressive
treatment in the management of patients with differentiated thyroid cancer (Cooper et
al. 2006, BTA and RCP guidelines 2007). It is unlikely that TSH suppression reduces
benign nodule size, however, it may prevent the development of new nodules and
reduce rate of growth (Papini et al. 1998, Zelmanovitz et al. 1998, Vermiglio et al.
2003, Gharib 2004). In addition, analysis of benign nodules indicates that there may
be a pathogenetic role of TSH because suppressive doses of levothyroxine result in
beneficial cytologic changes including an increase in colloid nodules from those
nodules previously classified hypercellular or adenomatous (Vermiglio et al. 2003).
It is well known that individual thyroid hormone concentrations are maintained
within narrow limits (Anderson er al. 2002) and that the heritable contribution to
serum TSH is as high as 65% (Panicker et al. 2008). One possibility is that patients
with higher TSH have a genetic predisposition to both higher TSH and cancer
(Panicker et al. 2008). However, if the increased cancer incidence was secondary to a
TSH receptor polymorphism, similar to the TSHR-Glu727 allele associated with
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lower TSH (Hansen et al. 2007), or a polymorphism in the thyroid hormone pathway
genes (Peeters et al. 2003) a clear genetic predisposition for thyroid cancer would be
expected. Instead, only 3–6% of nonmedullary thyroid cancer is familial (Sippel et al.
2007; Pal et al. 2001).
There are alternative explanations for the association between higher TSH and
thyroid cancer. There may be resistance to TSH at the level of the malignancy due to
TSH receptor silencing in the setting of aberrant DNA methylation (Xing er al. 2003),
but even in this situation the remaining healthy thyrocytes would be expected to
compensate, and for the relationship between higher TSH and cancer do not exist. If
TSH was truly carcinogenic, as suggested in a mouse model (Brewer et al. 2007;
Yeager et al. 2007), we could expect the absolute TSH to be consistently elevated to a
limitation, not to rise with age parallel to benign thyroid disease. The likelihood of
early end-organ damage leading to relative TSH resistance seems reasonable, but the
absence of a clear relationship between pathologic Hashimoto’s thyroiditis, higher
TSH and cancer weakens this hypothesis. Perhaps the most probable explanation for
the relationship between higher TSH and thyroid cancer incidence is that TSH, a
growth factor, leads to increased cancer detection. More than one third of patients
have occult microcarcinomas on thorough autopsy reports (Harach et al. 1985) and
yet only a small number of individuals are diagnosed with thyroid cancer each year.
TSH stimulation may cause occult microcarcinomas to grow to a detectable size.
Previous in vitro studies have indicated a relationship between TSH stimulation and
cancer aggression (Hoelting et al. 1993; Hoelting et al. 1995) In vitro, TSH stimulates
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invasion and growth of human thyroid cancer cell lines by protein kinase C (PKC)
stimulation. Activation of matrix metalloproteinases plays a key role in this invasion
(Yeh et al. 2006) and the impact of TSH on the metalloproteinases in healthy
surrounding thyroid tissue and the cancer foci has not been determined (Baldini et al.
2004). Data from Megan R. et al. also suggest that TSH facilitates extrathyroidal
extension of disease. Further studies are needed to define this relationship as
understanding it may be pivotal in understanding the pathogenesis of this disease.
Despite these supportive findings, there are a number of reasons that the function
of TSH in the development or progression of thyroid cancers has been minimized.
First, TSH receptor mutations in regions functionally associated with increased signal
transduction do not commonly occur in thyroid cancer (Matsuo et al. 1993). Second,
vitro studies have shown that other growth factors such as insulin-like growth factor-I
(IGF-I) have been shown to be more potent in stimulating thyroid cancer growth
(Derwahl et al. 1999, Mazzaferri 2000), and TSH requires cooperation with
insulin/IGF-1 to exert its proliferative effects (Kimura et al. 2001). Third, there is an
inverse relationship between TSH receptor mRNA levels and cancer aggressiveness
(Shi et al. 1993). Fourth, thyroid cancer is known to occur in subjects with a range of
TSH concentrations including in the suppressed contralateral lobe of hyperfunctioning
nodules (Satta et al. 1993). Finally, a recent genome-wide association study has
indicated that serum TSH concentrations are lower in patients carrying one of two
alleles associated with an increased risk of both papillary and follicular thyroid cancer
(Gudmundsson et al. 2009).
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Taken together, these findings suggest that stimulation of the TSH receptor via
increased serum TSH concentrations may play a role in the growth of benign and
malignant thyroid tumors, although it is unlikely that TSH acts solely. It has been
proposed that direct thyroid hormone-dependent cellular effects rather than
TSH-mediated mechanisms are responsible for the beneficial effects in patients
treated with suppressive T4 therapy (Brabant 2008).
Prediction of risk of DTC
Experts advocate thyroidectomy, regardless of cytology results in subjects with a
high clinical suspicion of malignancy (Hegedus et al. 2003; Hamming et al. 1990;
Hegedus 2004). However, few studies have attempted to integrate clinical or
laboratory parameters systematically with the results of FNAB into the selection
process of patients who need surgery especially in order to improve the diagnostic
accuracy of FNAB Thy3, Thy4. One previous report (Tuttle et al. 1998) aimed to
develop clinical criteria capable of predicting malignancy in 149 patients with an
FNAB diagnosis of follicular neoplasm and concluded that features such as gender,
nodule size, and character of the gland by palpation can be systematically integrated
into the decision analysis before surgical referral (Tuttle et al. 1998). We demonstrate
that the presenting TSH concentration is an additional useful parameter in the
prediction of probability of existing malignancy.
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CONCLUSION
Based on our study，TSH is a known thyroid growth factor and, may play a
central role in the development and progression of thyroid cancer. There is a
significant difference between serum TSH levels in patients with PTC and BTND, the
risk of malignancy in thyroid nodules increased with serum TSH concentration even
within the normal range. Within normal range TSH, an increased risk of DTC was
found in a TSH level above the population mean relative to below the mean. In
addition, there is also a significantly higher mean TSH in stage III and IV DTC than
stage I and II DTC. Despite unclear pathogenesis, the association between thyroid
cancer and higher TSH is independent of age.
In predicting the risk of DTC in patients presenting with thyroid nodules, serum
TSH may be able to serve as an adjunct to other well defined clinical parameters and
results of FNAB, especially the indeterminate, to identify those who require further
investigation and/or surgical intervention. This may be important for the simplicity
and availability of the measurement of serum TSH. We have also calculated a formula
helping predicting a diagnosis of thyroid malignancy, taking into account patient’s age,
gender, goiter type, and the serum TSH concentration, factors that we found to be
independently associated with likelihood of diagnosis of thyroid malignancy.
More prospective studies are required to establish the potentially important role
of TSH as another indicator in the prediction of thyroid malignancy in clinical
management of thyroid nodules. Further understanding of the role of TSH in DTC
may help with the prevention, diagnosis, and management of thyroid cancer.
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Tables and figures attached
TABLE 1-1. Patient and tumor characteristics
DTC BTND P value
n 223 1064
Gender
male 163 885 0.001
female 60 179 0.001
Mean age 45±0.5 52±0.6 0.008
Mean nodule size (cm) 2.2±0.3 3.6±0.05 0.0001
No. Of nodules
solitary 126 326 0.03
multiple 97 738 0.03
TABLE 1-2 Diagnostic result in cytology and histology
Histological diagnosis
Cytological
diagnosis
DTC BTND
DTC 205(TP) 182(FP)
(165 follicular lesions, 16
suspicious of malignancy, 1
malignancy)
BTND 18(FN)
(9 follicular cancer, 7 papillary
carcinoma, 2 Hurthle cell
carcinoma)
882(TN)
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TABLE 1-3 Free thyroid hormones and TSH levels
DTC BTND P value
All patients
n 223 1064
FT3(pg/ml) 3.7±0.8 3.6±1.3 NS
FT4(pg/ml) 10.6±0.07 10.9±0.4 NS
Mean TSH(uU/ml) 1.20±0.1 0.80±0.3 <0.0001
FNAB
indeterminate
n 103 181
Mean TSH(uU/ml) 1.6±0.4 0.90±0.6 0.06
Fig 1-1 prevalence of DTC according to serum TSH
Patients with serum TSH level within the normal range were divided into four
quartiles of similar size according to TSH values. Patients with serum TSH levels
lower or higher than the normal range values were considered separately.
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TABLE 1- 4 TSH and cancer stage
TNM stage No. of patients Mean
TSH(uU/ml)
P value
Ⅰand Ⅱ 190 0.74±0.3 0.003
Ⅲand Ⅳ 33 2.80±1.6
TABLE 1- 5 TAb and frequency of malignancy
No. Of patiences Frequency of
DTC(%)
PValue
TAb negative 1119 6.3 0.02
TAb positive 168 12.4
Fig 1-2 TSH levels according to the presence of TAb
In TAb positive subjects TSH (0.80±o.3 uU/ml) was significantly higher (P=0.002)
than in TAb negative patients (0.60±0.5 mU/m).
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Fig 1-3 TSH levels in DTC and BTND according to the presence of TAb
TSH levels in DTC were significantly higher than in BTND both in TAb positive
patients and in subjects with no TAb.
TABLE 1-6 Patient and tumor characteristics based on age
<45 yr ≥45 yr P value
N 517 770
DTC, n(%) 114(22) 109(14) 0.004
Mean TSH(uU/ml) 0.72±0.11 1.64±0.24 0.017
Gender
Male, n(%) 71(14) 168(22) 0.001
Female, n(%) 446(86) 602(78)
Mean nodule
size(cm)
2.4±0.02 2.8±0.01 0.006
>1 Nodule, n(%) 328(63) 507(66) 0.013
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Fig 1-4 Prevalence of DTC based on age
There were 11 patients with malignancy in the age group < 30 years, 58 in the age
group 30–44 year, 50 in the 45–59 year age group. In the age group ≥ 60 years, there
were 104 who had cancer. The change in prevalence of DTC according to age was not
linear and higher prevalence was observed at both extremes of age.
Fig 1-5 TSH level based on age
In the age categories <45 years and ≥45 years, patients with thyroid cancer have a
significantly higher mean TSH than those without cancer.
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Fig 1-6 TSH level based on age
Across all age categories, patients with thyroid cancer have a higher mean TSH.
Significance is established in the age 30-44 years and 45-59 years. P<0.05.
Table 1-7 Multivariate analysis of variable associated with higher TSH
Variable P value
Age 0.458
Thyroid cancer 0.033
Male gender 0.072
Nodule size 0.716
Nodule type 0.515
58
Table 1-8 Independent risk factors for diagnosis of thyroid cancer by
multivariable logistic regression analysis.
variable Adjusted adds
ratio
95% confidence
interval
P value
Male gender 2.42 1.53-3.57 <0.0001
Age 0.92 0.88-0.97 0.026
Solitary nodule 2.34 1.49-4.16 0.001
Nodule size 0.72 0.68-0.89 <0.0001
TSH(uU/ml)
<0.4 1.00
0.4-0.59 0.95 0.47-1.67 0.54
0.60-0.89 1.36 0.56-3.13 0.046
0.9-1.59 2.54 1.03-6.02 0.04
1.60-3.4 4.77 1.43-12.27 0.006
>3.4 4.45 1.39-8.36 0.012
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Part Ⅱ DIAGNOSTIC METHODS FOR PATIENTS
PRESENTING THYROID NODULES
History and physical examination
The history and physical examination remains the diagnostic cornerstones in
evaluating the patient with thyroid nodules and some risk factors may indicate a
suspicion of thyroid cancer (Table 2-1). When a patient presenting two or more risk
factors that indicate a high clinical suspicion, the likelihood of cancer approaches 100
percent (Hamming er al. 1990), however, a few of patients with malignancy have
suggestive findings, which often also occur in patients with benign thyroid nodules.
Since the majority of incidental nodules (<10mm) is not easy to be detected by
palpation, in which the risk of malignancy seems nearly as high as in larger nodules
(Papini er al. 2002). Whereas, the vast majority of these microcarcinomas does not
grow during long-term follow-up and does not cause clinically significant thyroid
cancer (Ito Y et al. 2003).
Laboratory investigations
For clinical examination can not sensitively identify thyroid dysfunction,
laboratory evaluation of thyroid function is routinely warranted. If serum thyrotropin
level is subnormal, levels of free thyroxine (FT4) or free triiodothyronine (FT3)
should be considered to document the presence and degree of hyperthyroidism.
Approximately 10 percent of patients with a nodule have a suppressed level of serum
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thyrotropin, which suggests a benign hyperfunctioning nodule (Wong CKM, et al.
2000). If the serum thyrotropin concentration is elevated, a serum antithyroperoxidase
antibody level should be obtained to confirm Hashimoto’s thyroiditis. However, the
finding of an elevated level does not obviate the need for a fine-needle aspiration
biopsy, since the practitioner must rule out a coexisting cancer, including lymphoma,
which accounts for only 5 percent of thyroid cancers but is associated with
Hashimoto’s thyroiditis (Pasieka et al. 2000). Most patients with thyroid cancer are
euthyroid. If a patient has a family history of medullary thyroid cancer or multiple
endocrine neoplasia type 2, a basal serum calcitonin level should be tested, and an
elevated level suggests medullary thyroid cancer. Before surgery is performed,
investigation for primary hyperparathyroidism and pheochromocytoma should also be
carried out. Serum calcitonin is not routinely measured in patients who have no
suggestive family history, since medullary carcinoma is present in only about 1 of 250
patients with a thyroid nodule (Elisei et al. 2004).
Imaging of the thyroid nodule
Radionuclide Scanning
Radionuclide scanning, which is performed with iodine-123, iodine-131, or
technetium-99m–labeled pertechnetate, may be used to identify whether a nodule is
functioning. A functioning nodule, with or without suppression of extranodular uptake,
is nearly always benign, while a nonfunctioning nodule, constituting approximately
90 percent of nodules, has a 5 percent risk of being malignant. In the patient with a
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suppressed level of serum thyrotropin, radionuclide confirmation of a functioning
nodule may obviate the need for biopsy. A scan can also indicate the number of
nodules and can reveal extension of the thyroid, but cannot be used to accurately
measure the size of a nodule. Iodine isotopes, which are both trapped and bound in the
thyroid, are preferred, since 3 to 8 percent of nodules that appear functioning on
pertechnetate scanning may appear nonfunctioning on radioiodine scanning, and a
few of those nodules may be thyroid cancers (Shanmbaugh et al. 1974).
Ultrasonography
Ultrasonography can accurately detect nonpalpable nodules, estimate the size of
the nodule and the volume of the goiter, and differentiate simple cysts, which have a
low risk of being malignant, from solid nodules or from mixed cystic and solid
nodules, which have a 5 percent risk of being malignant. Among patients who had
been referred for evaluation of a palpable thyroid abnormality, ultrasonography could
alter the clinical management in two thirds of cases (Marqusee et al. 2000), mainly by
finding nodules that were smaller than 1 cm (which were not considered to require
further evaluation) in 20 percent of the patients and by discovering additional nodules
(which required biopsy) in 24 percent of the patients. Though the characteristics
found by ultrasonography, hypoechogenicity, microcalcifications, irregular margins,
increased nodular flow visualized by Doppler, and especially the evidence of invasion
or regional lymphadenopathy, are associated with an increased risk of cancer, it is not
reliable to distinguish between benign and cancerous lesions. Ultrasonography also
provides guidance for diagnostic procedures (e.g., fine-needle aspiration biopsy) as
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well as therapeutic procedures (e.g., cyst aspiration, ethanol injection, or laser therapy)
and facilitates the monitoring of the effects of treatment.
CT, MRI and PET
Computed tomography (CT) and magnetic resonance imaging (MRI) also cannot
reliably differentiate between malignant and benign nodules, thus these tests are rarely
preferred in the evaluation of a nodule. An exception is in the diagnosis and
evaluation of substernal goiters, since these imaging techniques can assess the extent
of the goiter more precisely than other techniques and can evaluate tracheal
compression. Positron-emission tomography (PET) evaluating glucose metabolism by
using fludeoxyglucose (fluorodeoxyglucose) F-18 may help in distinguishing benign
from malignant nodules, but its use is limited by cost and accessibility and it cannot
replace biopsy.
Fine-needle aspiration biopsy
Fine-needle aspiration can provide the most direct and specific information about
a thyroid nodule comparing with morphology. It has advantages of performing on an
outpatient, being relatively inexpensive and easy to learn. Complications are also rare
and primarily involve local discomfort or bleeding. Compared with surgery performed
on the basis of clinical findings alone, this technique has been considered to reduce
the number of thyroidectomies by approximately 50 percent, to roughly redouble the
surgical confirmation of carcinoma, and to reduce the cost of medical care by 25
percent (Mazzaferri et al. 1993). If FNAB is guided by ultrasonography, the number
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of sufficient samples obtained increases, especially in nodules that are partly cystic,
and repeated biopsy reduces by half the rate of insufficient samples (to about 10
percent). Fine-needle aspiration has diagnostically useful results in about 80 percent
cases (Burch 1995). If radionuclide scanning in patients with a FNAB follicular
neoplasm (which occurs in approximately 15 percent of nodules, of which only 20
percent turn out to be malignant) shows a functioning nodule, surgery can be avoided,
since the risk of cancer is inappreciable. If fine-needle aspiration reveals a cystic
lesion or a mixture of cystic and solid components, aspiration of a possible solid
component should be performed, since the risk of cancer is the same as that for a solid
nonfunctioning nodule (Kuma er al. 1992; Bennedbak et al. 1998).
Taken together clinical management of thyroid nodules should be guided by the
results of US evaluation and FNA biopsy. The scheme for the diagnosis and
management of palpable thyroid nodules is shown in figure 2-1.
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Tables and figures attached
Table 2-1 Factors Suggesting Increased Risk of Malignant Potential
High suspicion
Family history of MTC, MEN 2, or PTC
Growing nodule, especially during levothyroxine therapy
Firm or hard consistency
Fixed nodule
Paralysis of vocal cords
Cervical lymphadenopathy
Distant metastases
Moderate suspicion
Age<20 or >70years
Male sex
History of head or neck irradiation
Nodule >4cm in diameter or partially cystic
Symptoms of compression, including dysphonia, dysphagia, dyspnea, hoarseness,
and cough
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Fig 2-1. Flowchart indicating a scheme for the diagnosis and management of palpable
thyroid nodules.
Thyroid nodule
History, physical examination
Thyroid US with focus on risk
factors for malignancy
TSH, Free thyroxine, and/or
calcitonin
Normal or high
thyrotropin level
Low thyrotropin or MNG
in iodine-deficient region
Normofunctioning or
cold on thyroid
scintigraphy
Functioning
nodule
Nodule <1cm without
suspicious history or
suspicious US finding
Nodule >1cm or <1cm
with suspicious history or
suspicious US finding
Follow- up Suspicion for malignancy
by clinical or US criteria
NO YES
FNAB
Benign
Follicular lesion, suspicious,
malignant Nondiagnostic results
Radioiodine;
follow up;
surgery;
er al.
Repeat FNAB
Nondiagnostic results
Surgery
Follow up; surgery;
levothyroxine
therapy et al.
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